Biote Corp. reports developments tied to its hormone optimization and healthy aging business, which supports Biote-certified medical providers through training, practice development, operational services and personalized hormone therapy programs. Company updates commonly cover procedure revenue, dietary supplement sales, new provider and clinic growth, commercial team expansion and technology or sales investments aimed at the practitioner network.
Biote news also includes quarterly financial results, outlook commentary, share repurchases, organizational changes and product-supply matters. Its operating updates distinguish procedure-based revenue from Biote-branded dietary supplements and have included disclosures related to Asteria Health, the company’s wholly owned 503B manufacturing subsidiary.
Biote (NASDAQ: BTMD) reported third quarter 2025 results with revenue of $48.0M (down 6.7% YoY), gross margin 71.8%, net income of $9.2M and diluted EPS of $0.22. Procedure revenue fell 10.4% while dietary supplements grew 8.4%. Adjusted EBITDA was $12.9M with a 26.9% margin. The company repurchased ~1 million Class A shares and completed share repurchase payments to settle legacy earnout obligations totaling $12.5M and an agreed $18.5M payment due Jan 2026. Biote reiterated 2025 guidance: revenue above $190M and Adjusted EBITDA above $50M.
biote (Nasdaq: BTMD) will release Q3 2025 financial results on Wednesday, November 5, 2025 after market close. A conference call to discuss results is scheduled the same day at 5:00 p.m. ET.
Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (international) or via the live webcast. A replay of the webcast will be posted on the Events page of the biote investor relations website shortly after the event concludes.
Biote (NASDAQ: BTMD), a preventive healthcare company specializing in hormone optimization, reported Q2 2025 financial results with revenue of $48.9 million, slightly down from $49.2 million year-over-year. The company achieved a gross profit margin of 71.6% and net income of $3.9 million ($0.10 per diluted share).
Key highlights include a 30.4% increase in dietary supplement revenue, though procedure revenue declined 8.4%. Adjusted EBITDA grew 19.1% to $15.2 million, with margin expanding to 31.1%. The company initiated an organizational restructuring in May 2025 and revised its fiscal 2025 guidance downward to revenue above $190 million and Adjusted EBITDA above $50 million, compared to previous guidance of $202-208 million and $59-64 million respectively.
Biote (NASDAQ:BTMD), a provider of personalized hormone optimization and therapeutic wellness solutions, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, after market close.
The company will host a conference call at 5:00 p.m. ET the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A webcast replay will be available on Biote's Investor Relations website after the event.
Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has announced its upcoming first quarter 2025 financial results release. The company will present its results on Wednesday, May 7, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Investors can access the conference call via U.S. toll-free number (844) 481-2820 or International number (412) 317-0679. A webcast replay will be available on the company's Investor Relations website Events page after the call concludes.
Biote Corp (NASDAQ: BTMD) announced significant insider stock purchases, with several Board of Directors members and CEO Bret Christensen collectively acquiring approximately 260,000 shares through open market transactions.
Executive Chairman Marc Beer expressed confidence in the company's business strategy and long-term outlook, specifically highlighting CEO Christensen's capabilities to implement decisive changes for business growth. Beer emphasized Christensen's extensive background in diagnostic, therapeutic, and medical device healthcare sectors as key qualifications for leading Biote's expansion.
Biote (NASDAQ: BTMD) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year revenue increased 6.4% to $197.2 million, with procedure revenue reaching $150.3 million. The company achieved a gross profit margin of 70.5% and net income of $0.05 million.
In Q4 2024, revenue grew 9.0% to $49.8 million, with procedure revenue up 5.0%. However, Q4 net income decreased to $3.5 million ($0.10 per share) from $12.1 million ($0.18 per share) in Q4 2023. The quarter saw a 71.8% gross profit margin and Adjusted EBITDA of $15.1 million.
For fiscal 2025, Biote projects procedure revenue growth of 2-4% and dietary supplements revenue increase of 5-10%. The company plans to focus on maximizing top-tier providers, expanding practitioner network, and strengthening commercial execution.
Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025, after market close.
The company will host a conference call at 5:00 p.m. ET on the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A live webcast will be available, and a replay will be posted on the Events page of Biote's Investor Relations website following the call.